Kyras Therapeutics Overview
- Year Founded
-
2015
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Kyras Therapeutics General Information
Description
Developer of drugs designed to cure cancer and other developmental disorders. The company's drugs address currently incurable cancers and developmental disorders caused by RAS gene mutations, enabling healthcare providers to cure their patients.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 430 East 29th Street
- Suite 1005
- New York, NY 10016
- United States
Kyras Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 01-Apr-2018 | 000 | Completed | Out of Business | ||
| 3. Grant | 16-Nov-2017 | 000 | 000 | Completed | Generating Revenue | |
| 2. Early Stage VC (Series A) | 10-Dec-2015 | $5M | $5M | 0000 | Completed | Generating Revenue |
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Kyras Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.000 |
Kyras Therapeutics Patents
Kyras Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20170158702-A1 | Multivalent ras binding compounds | Inactive | 02-Dec-2015 | 0000000000 |
Kyras Therapeutics Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Carlo Rizzuto Ph.D | Co-Founder, Board Member & Chief Executive Officer | ||
| Joseph Vacca Ph.D | Chief Scientific Officer |
Kyras Therapeutics Board Members (3)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bradley Bolzon Ph.D | Versant Ventures | Board Member | 000 0000 |
| Carlo Rizzuto Ph.D | Self | Co-Founder, Board Member & Chief Executive Officer | 000 0000 |